ZymoGenetics begins phase 3 study with rhThrombin

By Jennifer Chiou

New York, Oct. 27 - ZymoGenetics, Inc. launched a phase 3 clinical study to test the efficacy and safety of recombinant human Thrombin (rhThrombin) in patients undergoing surgery.

The study will compare rhThrombin to bovine-derived thrombin and is designed to support the use of rhThrombin as an aid for blood-loss control during surgery.

The randomized, double-blinded phase 3 clinical trial with rhThrombin will evaluate spinal, liver resection, peripheral artery bypass and arteriovenous graft construction surgeries.

"The thrombin market is attractive and the need exists for a safer method of hemostasis. We believe that our rhThrombin may address that need," said Bruce L. A. Carter, president and chief executive officer, in a news release.

"Patients need safer treatments for surgical bleeding," phase 2 clinical investigator William C. Chapman said in the release.

"Because recombinant products can be manufactured to high levels of purity and don't contain animal blood products, I believe rhThrombin could replace plasma-derived bovine thrombin."

ZymoGenetics is a Seattle biopharmaceutical company focused on bleeding, autoimmune diseases and cancer.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.